[go: up one dir, main page]

WO1992018531A1 - Analogues de somatocrinine - Google Patents

Analogues de somatocrinine Download PDF

Info

Publication number
WO1992018531A1
WO1992018531A1 PCT/EP1992/000723 EP9200723W WO9218531A1 WO 1992018531 A1 WO1992018531 A1 WO 1992018531A1 EP 9200723 W EP9200723 W EP 9200723W WO 9218531 A1 WO9218531 A1 WO 9218531A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
xaa
ala
compound
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1992/000723
Other languages
English (en)
Inventor
Arthur Martin Felix
Edgar Philip Heimer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to JP92506862A priority Critical patent/JPH05507939A/ja
Priority to AU14485/92A priority patent/AU662731B2/en
Publication of WO1992018531A1 publication Critical patent/WO1992018531A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention relates to analogs of human growth hormone releasing factor and to fragments thereof.
  • the pharmaceutical compositions of the invention can be used to treat a variety of growth hormone related problems in human beings and for performance enhancement in animals.
  • Human growth hormone releasing factor (hGRF or GRF) has been isolated from human islet cell tumor and structurally characterized by Guillemin et al., Science, 218. 585-587 (1982) and Rivier et al., Nature, 30H, 276-278 (1982). The isolation and characterization of GRF, while sought for decades, was previously unsuccessful due to its presence in very small quantities. Human hypothalamic growth hormone releasing factor (hGRF) has been shown to have the same structure as GRF isolated from islet cell tumor, by Bohlen et al, Biochem. and Biophys. Res. Comm., H4, 930-936 (1983).
  • GRF 1-44
  • GRF (1-40 SEQ ID NO: 2
  • GRF is further distinguished in having an amide group at the carboxy terminus.
  • GRF has great therapeutic utility in those instances where growth hormone is indicated.
  • GRF may be used in the treatment of hypopituitary dwarfism, diabetes due to growth hormone production abnormalities, enhancement of wound healing, treatment of burns, retardation of the aging process or osteoporosis or bone healing.
  • GRF has utility in the agricultural field.
  • Examples of agricultural uses include, enhanced meat production of fowl or animals raised for food such as pigs, cattle or the like to permit earlier marketing or to produce larger animals in similar time on feed or improve the lean to fat ratios.
  • GRF may also stimulate milk production in dairy cows and egg production in chickens.
  • GRF can be used in aquaculture, for example, for raising or accelerating the growth of fish and other cold-blooded marine animals. The successful isolation of GRF was due partly to the discovery that pancreatic tumors associated with acromegaly ectopically produced large quantities of GRF. Three forms of GRF, consisting of peptides homologous from the amino terminus of 44, 40 and 37 amino acids, were isolated.
  • the 44 amino acid amidated form of GRF is considered to be the parent molecule.
  • a wide variety of synthetic analogs have been produced. They consist of biologically active fragments of the original polypeptide which incorporate various amino acid substitutions. The changes have been specifically engineered to often yield synthetic analogs with biological properties superior to those of the parent molecule.
  • linear peptides are very flexible molecules and lack a well-defined conformation. Each amino acid in a linear peptide is exposed to the surrounding milieau resulting in greater susceptibility to enzymatic and chemical degradation.
  • GRF analogs which exhibit maximum biological activity in terms of, for example, potency, effectiveness, and stability together with resistance to enzymatic, non-enzymatic and chemical degradation, deamidation, and oxidation.
  • the present invention relates to compounds having a sequence of twenty-nine to forty-four amino acids (SEQ ID NO: 6) wherein Xaa at position 1 is His, 3-MeHis, desNH2Hi s > Tyr, or desNH2Tyr; Xaa at position 2 is Val, Leu, He, Ala, D-Ala, N-methyl-D-Ala, Gly, Nle, or Nval; Xaa at position 8 is Gin, Ser or Thr; Xaa at position 15 is Ala or Leu; Xaa at position 27 is Met, Nle, or Leu; Xaa at position 28 is Ser or Asn; Xaa at position 29 is an amino acid sequence (SEQ ID NO: 7) or fragments thereof where the fragment is reduced in number by one to fifteen amino acid residues from the carboxyl-terminus, where the carboxyl-terminus can be the free carboxylic acid or the corresponding amide, and the pharmaceutically acceptable acid or base addition salts thereof.
  • compositions in accordance with the invention include such analogs which are between twenty-nine and forty-four residues in length dispersed if desired, in a pharmaceutically or veterinary acceptable liquid or solid carrier.
  • Such pharmaceutical compositions can be used in clinical medicine, both human and veterinary. Moreover, they can be used to promote the growth of warm and cold-blooded animals. They can also be used to treat growth related disorders and improve growth performance in warm and cold-blooded animals.
  • the GRF peptides of this invention are useful in methods for stimulating the release of growth hormone from the pituitary for use in the treatments described above.
  • GRF human growth hormone releasing factor
  • SEQ ID NO: 1 Science, 2£i, 585, (1982)] or biologically active fragments having at least the first 29 amino acids of the full polypeptide and displaying growth hormone releasing activity.
  • amino group at the N-terminus appears to the left and the carboxyl group or carboxyl terminus at the C-terminus to the right.
  • Amino acid is taken to mean one of the naturally occurring amino acids typically found in proteins comprising Gly, Ala, Val, Leu, lie, Ser, Thr, Lys, Arg, Asp, Asn, Glu, Gin, Cys, Met, Phe, Tyr, Pro, Trp, and His.
  • Nle means norleucine;
  • Nval means norvaline. Where the amino acid residue has an isomeric form, it is the L-form of the amino acid that is represented unless otherwise expressly indicated.
  • # (where # is the sequence number and "SEQ ID No: #” refers to a specific amino acid sequence of said sequence number given in the sequence listing of Table 3 at the end of the Examples) refers to the free carboxylic acid and free amide forms of the compound, respectively, at the C-terminus. In the event neither suffix is used, the expression is intended to encompass both forms.
  • Boc-SEQ ID NO: # - PAM resin refers to a protected sequence of SEQ ID NO: # where Boc protects the amino group at the N-terminus and PAM-resin protects the C-terminus.
  • the compounds can encompass the free carboxylic acid form or the amide form.
  • Analogs of GRF are indicated by setting forth the substituted amino acid in brackets before “GRF”; for example, “[Hisl,Alal5]-GRF” indicates a polypeptide having an amino acid sequence corresponding to GRF in which a histidine residue has been substituted for the tyrosine residue at position 1 and an alanine residue has been substituted for the glycine residue at position 15.
  • Numbers in parentheses following "GRF” indicate fragments of the full polypeptide by giving the position numbers of the amino acid residues; for example, GRF (1-29) indicates a fragment having the first 29 amino acids of the full sequence.
  • the invention relates to compounds having a sequence (SEQ ID NO: 6) wherein Xaa at position 1 is His, 3-MeHis, desNH2H ⁇ s, Tyr » or desNH2Tyr; Xaa at position 2 is Val, Leu, He, Ala, D-Ala, N-methyl-D- Ala, Gly, Nle or Nval; Xaa at position 8 is Gin, Ser or Thr; Xaa at position 15 is Ala or Leu; Xaa at position 27 is Met, Nle, or Leu; Xaa at position 28 is Ser or Asn; Xaa at position 29 is an amino acid sequence (SEQ ID NO:7) or fragments thereof where the fragment is reduced in number by one to fifteen amino acid residues from the carboxyl- terminus, where the carboxyl-terminus can be the free carboxylic acid or the corresponding amide, and the pharmaceutically acceptable acid or base addition salts thereof.
  • compositions in accordance with the invention include such analogs which are between twenty-nine (29) and forty- four (44) residues in length dispersed in a pharmaceutically or veterinary acceptable liquid or solid carrier.
  • Such pharmaceutical compositions can be used in clinical medicine, both human and veterinary. Moreover, they can be used to promote the growth of warm and cold-blooded animals as discussed above.
  • This invention is based on the discovery that the asparagine at position 8 and the glycine residue at position 15 of the GRF molecule, together with the tyrosine residue at position 1 and/or the alanine residue at position 2, can be replaced by a different appropriately selected amino acid producing a GRF analog having resistance to the formation of biologically inactive GRF analogs and enhanced biological potency for stimulating the release of growth hormone from the pituitary. It was found that replacing the asparagine residue at position 8 with a different appropriately selected amino acid prevents the slow deamidation of asparagine to the biologically inactive isoaspartic acid, especially at physiological pH (about 7.4).
  • methionine residue at position 27 and/or the serine residue at position 28 can also be replaced in the same manner, also producing a GRF analog having enhanced biological potency. It was also found that replacing the methionine residue at postion 27 with a different appropriately selected amino acid prevents the oxidation of methionine to methionine sulfoxide.
  • Various methods well known in the art may be used to select a particular amino acid for substitution in GRF at a particular position.
  • One such method is to select a substitute amino acid so as to enhance the amph ⁇ philic character and helical structure of the resulting polypeptide as demonstrated by helicity and hydropathicity analysis.
  • the resultant peptides may bind more efficiently to the receptor and may be more stable to proteolytic breakdown thereby enhancing biological potency.
  • Helicity and hydropathicity analyses are done by conventional methods known in the art.
  • substitutions of appropriately selected amino acid residues at positions 8 and 15 of the GRF molecule together with substitutions of appropriately selected amino acid residues at positions 1 and/or 2, have enhanced biological activity and enzyme resistance. Additional substitutions of appropriately selected amino acid residues at positions 27 and/or 28 of the GRF molecule, concomitant to the substitution at the 8 and 15 positions together with the 1 and/or 2 positions, produce a multisubstituted GRF analog yielding peptides having increased biological potency in effecting the release of growth hormone by the pituitary.
  • Selected amino acids for substitution at the appropriately selected positions include but are not limited to tyrosine, desNH2tyrosine, alanine, D-alanine, leucine, isoleucine, methionine, valine, asparagine, serine, norleucine, histidine, desNH2histidine, and 3 -methylhistidine.
  • the acid or amide of the 29 amino acid GRF molecule or a GRF analog greater than about 29 amino acids and less than 44 amino acids in length in addition to the substitution at the positions discussed above have enhanced biological activity and increased enzyme resistance.
  • Preferable fragments of SEQ ID NO: 7 include Arg, the first amino acid residue of SEQ ID NO: 7 and Arg-Gln-Gln-Gly, the first four amino acid residues of SEQ ID NO: 7.
  • Representative compounds of the present invention include:
  • SEQ ID NO: 15-OH SEQ ID NO: 16-OH: SEQ ID NO: 17-OH, where Xaa 2 is D-Ala;
  • polypeptides of this invention can be prepared by many procedures including, but not limited to, recombinant DNA methods, solid phase peptide synthesis techniques, or solution phase peptide synthesis techniques.
  • a DNA sequence containing the structural code for GRF could be inserted into a replicable expression vehicle under the control of appropriate control elements including a promoter-operator sequence and a sequence coding for a ribosome binding site.
  • the expression vehicle would then be used to transform a host microorganism, such as a bacterium, which would be grown up and subjected to conditions under which it would express GRF. It will be recognized by those of ordinary skill in the art that in the present stated technology only natural amino acids can be introduced by recombinant methods.
  • recombinant DNA techniques can be utilized to prepare the peptide containing the natural amino acid residues which could then be coupled with fragments containing non-naturally occurring amino acids by procedures well known in the art.
  • Peptides may be prepared using solid phase synthesis, such as that described by Merrifield, J. Am. Chem. Soc, fi ⁇ , 2149 (1963), although other equivalent chemical syntheses known to one of ordinary skill may be used.
  • Solid phase synthesis is commenced from the C-terminal end of the peptide by coupling a protected amino acid via a benzyl ester linkage to a chloromethylated resin or a hydroxymethyl resin or via an amide bond to a benzhydrylamine (BHA) resin or methylbenzhydrylamine (MBHA) resin.
  • BHA benzhydrylamine
  • MBHA methylbenzhydrylamine
  • the acid form of the novel analogs may be prepared by the solid phase peptide synthesis procedure using a benzyl ester-resin or phenylacetamidomethyl-resin as a solid support.
  • the polypeptide may be purified by preparative high performance liquid chromatography (HPLC) and then shown to be homogeneous by analytical HPLC, isoelectric focusing or high voltage thin layer electrophoresis. Amino acid analysis may be performed to confirm the expected amino acid composition.
  • the corresponding amides may be produced by using benzhydrylamine or methylbenzhydrylamine resin as the solid support for solid phase peptide synthesis.
  • benzhydrylamine or methylbenzhydrylamine resin as the solid support for solid phase peptide synthesis.
  • the C-terminal amino acid for example, Arg, is protected at the
  • Boc-Arg(Tos)-OH can be first coupled to the benzhydrylamine resin using dicyclohexyl- carbodiimide (DCC) at about 25°C for 2 hours with stirring.
  • DCC dicyclohexyl- carbodiimide
  • the ⁇ -amino protecting group is removed, using trifluoroacetic acid (TFA) in methylene chloride or TFA alone. The deprotection is carried out at a temperature between about 0°C and room temperature.
  • Boc-protected amino acids are coupled step wise in the desired order or as an alternative to adding each amino acid separately in the synthesis, some may be activated prior to its addition to the solid phase synthesizer.
  • the selection of an appropriate coupling reagent is known to one of ordinary skill in the art. Particularly suitable is DCC.
  • Each protected amino acid is introduced in the desired amino acid sequence into the solid phase reactor in excess, and the coupling may be carried out in a medium of dimethylformamide (DMF) or methylene chloride (CH2CI2) or mixtures thereof.
  • DMF dimethylformamide
  • CH2CI2 methylene chloride
  • the coupling procedure is repeated before removal of the N ⁇ -amino protecting group prior to the coupling of the next amino acid.
  • the success of the coupling reaction at each stage of synthesis may be monitored by procedures well known in the art. A preferred method of monitoring the synthesis is by the ninhydrin reaction.
  • the coupling reactions can be performed automatically, for example, using a Vega Model 1000, a Model 250 or Model 296 Peptide Synthesizer or Applied Biosystems Model 430A or 431 A Peptide Synthesizer.
  • Cleavage of the peptide from the resin can be effected using procedures well known in peptide chemistry. Reaction with hydrogen fluoride in the presence of scavengers such as p-cresol and dimethylsulfide at 0°C for 1 hour may be followed by a second reaction with hydrogen fluoride in the presence of p-cresol for 2 hours at 0°C.
  • scavengers such as p-cresol and dimethylsulfide at 0°C for 1 hour
  • polypeptides of the invention can be effected using procedures well known in peptide chemistry. As previously indicated, the subject polypeptides may be purified using preparative HPLC; however, other known chromatographic procedures such as gel permeation, ion exchange and partition chromatography or countercurrent distribution can also be employed.
  • compositions in accordance with the invention include analogs of 29 to 44 amino acids in length, or a nontoxic salt of any of these, dispersed in a pharmaceutically or veterinarily acceptable liquid or solid carrier.
  • Such pharmaceutical compositions can be used for therapeutic or diagnostic purposes in clinical medicine, both human and veterinary. For example, they are useful in the treatment of growth-related disorders such as hypopituitary dwarfism and diabetes resulting from abnormalities in growth hormone production.
  • they can also be used to stimulate the growth or enhance feed efficiency of animals raised for meat production, to improve the quality of meat, to enhance milk production, and to stimulate egg production.
  • they can be used in agriculture, for example, for raising or accelerating the growth of fish and other cold blooded marine animals.
  • Appropriate dosages of the polypeptides of the invention to be administered will vary somewhat depending on the individual subject and the condition being treated. The skilled worker will be able to determine appropriate dosages based on the known circulating levels of growth hormone associated with normal growth and the growth hormone releasing activity of the polypeptide.
  • Compounds of this invention have increased potencies in vitro that are at least 2.5 times greater than that of GRF-(l-44)-NH2 (SEQ ID NO: I-NH2). Thus, these analogs can be administered in significantly lower dosages than if growth hormone releasing factor were given for the same purpose.
  • treatment of growth-related disorders will necessitate varying dosages from individual to individual depending upon the degree of insufficiency of growth hormone production.
  • a dosage range of from about 0.04 ⁇ g/kg/day to about 30.0 ⁇ g/kg/day (subcutaneous) based on body weight of the subject may be used to stimulate release of growth hormone.
  • the dosage employed to stimulate growth activity in livestock will be significantly higher (per kg.
  • a dosage in the range of from about 0.4 ⁇ g/kg/day to about 30 ⁇ g/kg/day subcutaneously may be used to stimulate release of growth hormone from the pituitary.
  • a method of treating growth-related disorders characterized by insufficient production of growth hormone which comprises administering an amount of the analogs of this invention sufficient to stimulate the production of growth hormone to levels associated with normal growth.
  • Normal levels of growth hormone vary considerably among individuals and, for any given individual, levels of circulating growth hormone vary considerably during the course of a day. In adult humans, normal serum levels of growth hormone have been reported to vary from about 0 to about 10 nanograms/ml. In children, normal serum levels of growth hormone have been reported to vary from about 0 to about 20 nanograms/ml.
  • Treatment is administered as early as possible following diagnosis of growth hormone deficiency. Treatement can begin as early as 2 to 3 years of age and can extend up to about 18 to 19 years of age and, in some individual cases, up to about 25 years.
  • the polypeptides of the invention can be administered in the form of human or veterinary pharmaceutical compositions which can be prepared by conventional pharmaceutical formulation techniques.
  • Compositions suitable for oral, intravenous, subcutaneous, intramuscular, intraperitoneal or intranasal administration may be employed.
  • a suitable dosage form for pharmaceutical use is from about 0.01 to about 0.5 mg of the compound of the invention, which may be lyophilized for reconstitution with sterile water or saline.
  • the composition should be maintained at a pH below about 8.0 in order to maintain the stability of the analog.
  • Serum albumin from the species being treated for example, human serum albumin in the case of humans, bovine serum albumin in the case of cows and so forth
  • polypeptides of this invention describe GRF analogs which possess, among other properties, enhanced stability to enzymatic (dipeptidylpeptidase-IV) degradation and enhanced biological activity.
  • optically active protected amino acids in the L-configuration were employed except where specifically noted.
  • the protected amino acids were examined by thin layer chromatography on silica gel G plates and developed with chlorine-TDM.
  • Amino acid analysis was performed on a Waters Amino Acid Analyzer. The following abbreviations are used in the examples to indicate various protecting groups and reagents.
  • the analogs of this invention were prepared by sequential coupling of amino acids by a manual mode or by employing commercially available automated solid phase peptide synthesizers (for example, Vega Model 1000, Model 250 or Model 296 Peptide Synthesizer or the Applied Biosystems Model 431 A or 430A Peptide Synthesizer). N ⁇ -Boc-amino acids were used in the synthesis.
  • Trifunctional amino acids were protected as N ⁇ *-Boc-Arg(Tos)-OH, N «-Boc-His(Tos)-OH, N ⁇ *-Boc-Lys(2Cz)-OH, N ⁇ -Boc-Ser(Bzl)-OH, N ⁇ -Boc-Thr(Bzl)-OH, N «-Boc-Asp(cHex)-OH, and N ⁇ -Boc-Tyr(Dcb)-OH.
  • the free carboxylic acid form of the GRF compound was formed in the examples below. The examples, unless otherwise stated, were carried out as stated. Temperatures are in degrees celsius.
  • Boc-Gly-PAM-resin (Bachem, 50 g, 0.76 mmol/g) was charged into the reaction vessel of a Vega 296 Peptide Synthesizer and solid phase peptide synthesis (SPPS) performed by the DCC procedure for a total of 9 cycles to give protected Boc-SEQ ID NO: 25-PAM-resin, ⁇ Boc- [Leu 7,Asn 8]-GRF(23-32)-PAM-resin ⁇ .
  • SPPS solid phase peptide synthesis
  • the crude material (100 mg) was dissolved in 20 mL of 0.1% TFA/H2O, filtered and loaded onto a prep-pak YMC-Basic HPLC column (4.8 x 30 cm). The column was eluted with (A) H2O (0.1% TFA) - (B) CH3CN (0.1% TFA) in a linear gradient from 20% (B) to 45% (B) in 90 minutes with a flow rate of 50 mL/min.
  • the protected Boc-SEQ ID NO: 14-PAM-resin was cleaved with anhydrous HF (as in Example 1) to give 781 mg of crude peptide which was dissolved in 20 mL of 0.1% TFA/H2O, filtered and loaded onto a Prep-Pak YMC-Basic column (4.8 x 30 cm). The column was eluted with (A) H2O (0.1% TFA)- (B) CH3CN (0.1% TFA) in a linear gradient mode from 20% (B) - 45% (B) in 90 min. with a flow rate of 50 mL/min. Fractions were collected every 0.5 min. and analyzed by the analytical HPLC system. Fractions containing semi-pure product were combined, evaporated and lyophilized.
  • the semi-pure material was dissolved in 0.1% TFA/H2O and loaded onto a 2.2 x 25 cm Nucleosil C-18 column.
  • the column was eluted with (A) H2O (0.1% TFA) - (B) CH3CN (0.1% TFA) in a linear gradient mode from 25% (B) to 40% (B) in 90 min with a flow rate of 15 mL/min.
  • Fractions were collected every minute and aliquots analyzed by the analytical HPLC system.
  • the product emerged in fractions 43-53 which were combined, evaporated and lyophilized to give 75 mg of pure SEQ ID NO: 14-OH.
  • the product was shown to be homogeneous by analytical HPLC and gave the expected amino acid composition after hydrolysis (6N.
  • a 2.2 g portion of protected Boc-SEQ ID NO: 26-PAM-resin was subjected to 6 cycles of SPPS, as in Example 2, to give 2.1 g of protected [Boc-SEQ ID NO: 27-PAM-resin, ⁇ Boc-[Thr8,Alal5, Leu 2 7,Asn 8]-GRF (3-32)-PAM-resin).
  • a 1.0 g portion of protected Boc-SEQ ID NO: 27-PAM-resin was subjected to two additional cycles of SPPS to give protected Boc-SEQ ID NO: 12-PAM-resin. An aliquot (0.6 g) was cleaved with anhydrous HF to give 320 mg of crude peptide. HPLC purification (as in Example 2) gave 20 mg of pure SEQ ID NO: 12-OH.
  • a 2.2 g portion of protected Boc-SEQ ID NO: 26-PAM-resin (from Example 1) was subjected to 6 cycles of SPPS, as in Example 2, to give 2.1 g of protected Boc-SEQ ID NO: 28-PAM-resin, [Boc- [Ser8,Alal5,Leu 7,Asn 8]-GRF (3-32)-PAM-resin).
  • a 1.0 g aliquot of protected Boc-SEQ ID NO: 28-PAM-resin was subjected to two additional cycles of SPPS and the resultant protected peptide resin (0.94 g) cleaved with HF to give 0.53 g of crude peptide which was purified as in Example 2.
  • Boc-Gly-PAM-resin (10 g; 0.76 mmol g; 7.6 mmol) was charged into a reaction vessel and 23 cycles of SPPS carried out in a manual mode to yield 17.2 g of protected Boc-SEQ ID NO: 29-PAM-resin, ⁇ Boc- [Alal 5 ,Leu 2 7]-GRF(9-32)-PAM-resin ⁇ .
  • a 200 mg aliquot was cleaved with HF, purified by HPLC on a Nucleosil C-18, 10 micron 300 A column (2.2 x 25 cm) to give 2.5 mg of pure SEQ ID NO: 29-OH.
  • the protected peptide resin (0.46 g) was cleaved with HF to give 270 mg of crude SEQ ID NO: 17-OH where Xaa 2 is D-Ala which was purified by HPLC (as in Example 1) to yield 30 mg of product that was found to be essentially homogeneous by analytical HPLC and gave the expected amino acid composition after hydrolysis (6N HC1-1% TGA; 150°C; lh): Thr 0.97 (1), Ser 2.96 (3), Tyr 1.07 (1).
  • the purified product, SEQ ID NO: 31 -OH where Xaal is desNH2Tyr and Xaa 2 is D-Ala (40 mg) was shown to be essentially homogeneous by analytical HPLC and gave the expected amino acid composition after acid hydrolysis (6N HC1-1% TGA; 150°C; lh): Thr 1.04 (1), Ser 2.87 (3), Tyr 1.10 (1). (6N HC1-1% TGA; 110°C; 24h): Asp 1.96, Glu 5.19 (5), Ala 3.99 (4), Val 0.93 (1), Leu 4.91 (5), Lys 2.01 (2), Arg 3.10 (3).
  • the product was shown to be essentially homogeneous by analytical HPLC and gave the expected amino acid composition after acid hydrolysis (6N HC1-1% TGA; 150°C; lh): Thr 0.99 (1), Ser 2.96 (3), Tyr 2.04 (2). (6N HC1-1% TGA; 110°C, 24h): Asp 2.07 (2), Glu 5.10 (5), Gly 1.11 (1), Ala 3.10 (3), Val 1.77 (2), He 1.78 (2), Leu 5.03 (5), Phe 0.91 (1), Lys 2.09 (2), Arg 3.01 (3). Confirmation of structure was provided by FAB mass spectrometry. Calcd: (M+H)+ 3710.3. Found: 3709.6.
  • a 2.0 g portion of protected Boc-SEQ ID NO: 29-PAM-resin (from Example 5) was subjected to 6 cycles of SPPS to give 2 g of protected Boc-SEQ ID NO: 32-PAM-resin, ⁇ Boc-[Thr8-Alal5, Leu 2 ?]-GRF(3-32)- PAM-resin ⁇ .
  • a 0.93 g portion was subjected to 2 additional cycles of SPPS and the protected peptide resin cleaved with HF and purified by HPLC to give 29 mg of SEQ ID NO: 11-OH.
  • the product was shown to be essentially homogeneous by analytical HPLC and gave the expected amino acid composition after acid hydrolysis: (6N HC1-1% TGA; 110°C; 24h): Asp 2.05 (2), Thr 1.85 (2), Ser 2.80 (3), Glu 4.40 (4), Gly 1.09 (1), Ala 3.01 (3), Leu 5.05 (5), Tyr 0.98 (1), His 0.95 (1), Lys 1.99 (2), Arg 2.90 (3). (6N HC1; 110°C; 72h): Val 2.00 (2), He 2.00 (2), Phe 1.00 (1). Confirmation of structure was provided by FAB Mass Spectrometry. Calcd: (M+H)+ 3671.2. Found: 3670.7.
  • a 2.0 g portion of protected Boc-SEQ ID NO: 29-PAM-resin (from Example 5) was subjected to 9 additional cycles of SPPS to give 2.0 g of protected Boc-SEQ ID NO: 15-PAM-resin.
  • a 1 g portion was cleaved with HF to give 540 mg of crude peptide which was purified by HPLC to give 101 mg of SEQ ID NO: 15-OH.
  • the product was shown to be essentially homogeneous by analytical HPLC and gave the expected amino acid composition after acid hydrolysis (6N HC1-1% TGA; 110°C; 24h): Asp 3.09 (3), Thr 0.98 (1), Ser 2.87 (3), Glu 4.45 (4), Gly 1.09 (1), Ala 3.07 (3), Leu 5.04 (5), Tyr 1.02 (1), His 0.98 (1), Lys 2.01 (2), Arg 3.02 (3). (6N HC1-1% TGA; 110°C; 72h): Val 1.99 (2), He 1.94 (2), Phe 1.00 (1). Confirmation of structure was provided by FAB mass spectrometry. Calcd: (M+H) + 3644.2. Found: 3643.5.
  • Boc-Arg(Tos)-benzhydrylamine resin (10 g, 0.45 mmol/g) was charged into a 250 mL reaction vessel clamped to a Model S-500 shaker equipped with an RD-20 shaker head. Solid phase peptide synthesis was performed manually by the DCC/HOBt and BOP procedures for a total of 20 cycles to give 20.5 g of protected Boc-SEQ ID NO: 33-BHA-resin ⁇ Boc-[Alal5]-GRF(9-29)-BHA resin ⁇ A 1.5 g portion of the peptide-resin was removed, charged into a reaction vessel and solid phase synthesis continued for an additional 8 cycles to give protected Boc-SEQ ID NO: 8-BHA-resin where Xaal j s desNH2Tyr and Xaa 2 is D-Ala (1.4 g).
  • the purified product was shown to be homogeneous by analytical HPLC and gave the expected amino acid composition (Hydrolysis: 6N HCl, 110°C, 24h): Asp 1.90 (2), Thr 1.73 (2), Ser 3.05 (3), Glu 2.20 (2), Ala 4.06 (4), Val 0.80 (1), Met 1.02 (1), He 1.77 (2), Leu 4.25 (4), Tyr 0.94 (1), Phe 0.83 (1), Lys 1.89 (2), Arg 3.21 (3). Confirmation of structure was provided by FAB mass spectroscopy. Calcd: (M+H)+, 3343.9. Found: 3345.1.
  • Example 14 (intermediate from Example 14) was subjected to 8 cycles of solid phase synthesis to give 1.4 g of protected Boc-SEQ ID NO: 9-BHA-resin where Xaal j s esNH2Tyr and Xaa 2 is D-Ala.
  • a 0.9 g portion was cleaved with anhydrous HF (as in Example 14) to give 495 mg of crude peptide which was purified (as in Example 14) and 42 mg of pure SEQ ID NO: 9-NH2 where Xaal i s desNH2Tyr and Xaa 2 is D-Ala was obtained.
  • Boc-Gly-Pam-resin can be charged into a reaction vessel of an Applied Biosystems Model 430A Peptide Synthesizer and can be subjected to 31 cycles of solid phase peptide synthesis to give protected SEQ ID NO: 37-Pam-resin.
  • the protected peptide-Pam-resin can be treated with HF as in Example 1 to yield crude SEQ ID No: 37- OH.
  • a portion of this crude product can then be subjected to HPLC purification as in Example 2.
  • the desired product emerging in several fractions can be combined, evaporated and lyophilized.
  • the product can be shown to be homogeneous by analytical HPLC and confirmed by amino acid analysis and FAB mass spectrometry.
  • EXAMPLE 18 SYNTHESIS OF SEQ ID NO: 38-OH WHERE Xaa 2 ? is Nle
  • Boc-Gly-Pam-resin can be charged into a reaction vessel of an
  • the biological activity of the novel peptides were compared with that of a synthetic standard of the natural sequence of GRF(1- 44)-NH2 (SEQ ID NO: I-NH2) which was isolated from a human pancreatic tumor of an individual suffering from acromegaly (Salk Institute standard hp-GRF-NH2(NL-A-10)).
  • the assay for biological activity which is based on the abiHty to stimulate production of growth hormone in rat pituitary cells in tissue culture, was performed in the following manner.
  • the dispersed cells were separated by centrifugation (150 X g, 4 min.) and re-suspended in Hepes buffer containing neuraminidase (4 mg/ml), and 200 mg/ml ethylenediaminetetraacetic acid (EDTA) disodium salt pH 7.35, for 10 min.
  • centrifugation 150 X g, 4 min.
  • Hepes buffer containing neuraminidase 4 mg/ml
  • EDTA ethylenediaminetetraacetic acid
  • the cells were washed twice with plating medium and plated on multiwell-plates (1.5xl ⁇ 5 cells per ml) using the following defined medium: F-12/DMEM/BGJ(6:3:1) (Gibco: 430-1700/430-1600/320-2591) with 2 g BSA/L., 2.38 g Hepes/L., 50 mg Gentamycin/L (Schering Co.).
  • the medium in each well was supplemented either with the novel peptide or natural GRF(l-44)- NH2 (SEQ ID NO: I-NH2) at concentrations ranging from 3.1 to 200 fmol. per ml. of medium. Control wells contained no supplement.
  • Plating was done with this medium added with 2% fetal calf serum to ensure rapid fixation of the cells.
  • the cells were washed twice with the defined medium without fetal calf serum.
  • 900 ml of defined medium was added to each well plus 100 ml of the same medium containing each individual treatment, in triplicate. After 3 hours of incubation the medium was collected and diluted as required to conduct radioimmunoassay (RIA) for rat growth hormone.
  • RIAs were conducted using Sinha's anti-murine GH immune serum and procedures according to the National Pituitary Agency using protein A to precipitate antibody antigen complex. The results are summarized in Table 1.
  • AU swine were cannulated via the femoral artery under halothane/ketamine HCL/xylezine anesthesia for subsequent (2-3 days) blood sampling.
  • GRF analog was administered by subcutaneous injection in porcine gelatin.
  • Pretreatment (control) blood samples were taken every 30 min from 8:30-9:30 a.m. Treatment doses were administered beginning at 10:00 a.m.
  • One hr post-dosing animals were sampled at 10 min intervals; 2nd hr post-dosing, animals were sampled at 15 min intervals; 3rd hr post-dosing, animals were sampled at 30 min intervals. All samples were centrifuged and the serum fractions stored (-20°C) until assayed for GH.
  • porcine GH levels in porcine sera were measured by homologous double- antibody RIA, employing porcine GH standard (lot# AFP-10859C) supplied by Dr. A. Parlow (Research and Education Institute, Torrance, CA) and baboon anti-pGH sera (B-58: Hoffmann-La Roche).
  • porcine GH standard lot# AFP-10859C
  • the pGH antisera employed in these assays did not cross-react ( ⁇ .1600 ng/ml) with porcine FSH (follicle stimulating hormone), porcine ACTH (adrenocorticotrophic hormone), porcine PRL (prolactin), or human GH.
  • the least detectable GH concentration was 1.56 ng/ml (0.156 ng/100 ml sample), with 50% displacement observed at 12.13 ng/ml.
  • GH area under the curve (GH AUC) for the treatment period (0-360 min) was determined by trapezoidal summation.
  • Mean GH AUC and mean GH peak data were independently compared using a one-way analysis of variance (repeated measures ANOVA) and Fisher least significant difference (LSD 05).
  • GRF analogs Half-life stability of GRF analogs in aqueous solution was determined by reverse phase HPLC at 37°C.
  • GRF analogs were prepared as described above. GRF analogs were dissolved in 20 mL of H2O and then taken up in 1.0 mL of buffer solution (pH 7.40) containing 0.25M Na2HP ⁇ 4/H3P ⁇ 4 and 1.0 mM N--N3. The concentration of the GRF analogs was 0.15 mg/mL.
  • the HPLC system was a Laboratory Data Control (LDC) HPLC with a Waters C-18 column (3.9 x 300 mm, lO ⁇ ).
  • the detector was a LDC Spectromonitor III and the gradient delivery system was a Constametric II.
  • Tyr Ala Asp Ala lie Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gin 1 5 10 15
  • Tyr Ala Asp Ala lie Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gin 1 5 10 15 Leu Ser Ala Arg Lys Leu Leu Gin Asp lie Met Ser Arg Gin Gin Gly
  • Tyr Ala Asp Ala lie Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly
  • MOLECULE TYPE protein
  • SEQUENCE DESCRIP ⁇ ON SEQ ID NO:S:
  • Tyr Ala Asp Ala lie Phe Thr Xaa Ser Tyr Arg Lys Val Leu Gly Gin 1 5 10 15
  • Tyr Val Asp Ala lie Phe Thr Ser Ser Tyr Arg Lys Val Leu Ala Gin 1 5 10 15 Leu Ser Ala Arg Lys Leu Leu Gin Asp lie Leu Ser Arg Gin Gin Gly
  • Xaa Val Asp Ala lie Phe Thr Gin Ser Tyr Arg Lys Val Leu Ala Gin 1 5 10 15 Leu Ser Ala Arg Lys Leu Leu Gin Asp lie Leu Ser Arg Gin Gin Gly
  • MOLECULE TYPE peptide
  • SEQUENCE DESCRIP ⁇ ON SEQ ID N0:35:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Nouveaux analogues de somatocrinine possédant une séquence de vingt-neuf à quarante-quatre acides aminés (NO ID SEQ : 6), dans laquelle Xaa à la position 1 représente His, 3-MeHis, desNH2His, Tyr ou desNH2Tyr; Xaa à la position 2 repésente Val, Leu, Ile, Ala, D-Ala, Méthyl-D-Ala, Gly, Nle ou Nval; Xaa à la position 8 représente Gln, Ser ou Thr; Xaa à la position 15 représente Ala ou Leu; Xaa à la position 27 représente Met, Nle ou Leu; Xaa à la position 28 représente Met, Nle ou Leu; Xaa à la position 29 représente une séquence de restes d'acides aminés (NO ID SEQ : 7) ou ses fragments, le fragment étant diminué en nombre par un à quinze restes d'acides aminés à partir de l'extrémité carboxyle terminale, et l'extrémité carboxyle terminale pouvant être l'acide carboxylique libre ou l'amide correspondant; et leurs sels d'addition d'acide ou de base pharmaceutiquement acceptables. Ces nouveaux analogues de somatocrinine présentent une activité améliorée de libération de somatotrophine, une stabilité enzymatique et une stabilité améliorée de demi-vie dans une solution aqueuse, et on peut les administrer à un sujet souffrant d'un déficit de somatotrophine, ou au bétail ou à d'autres animaux à sang chaud, ainsi qu'aux poissons ou à d'autres animaux marins à sang froid, pour en améliorer la croissance.
PCT/EP1992/000723 1991-04-09 1992-04-01 Analogues de somatocrinine Ceased WO1992018531A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP92506862A JPH05507939A (ja) 1991-04-09 1992-04-01 成長ホルモン放出因子の類似体
AU14485/92A AU662731B2 (en) 1991-04-09 1992-04-01 Growth hormone releasing factor analogs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68283591A 1991-04-09 1991-04-09
US682,835 1991-04-09

Publications (1)

Publication Number Publication Date
WO1992018531A1 true WO1992018531A1 (fr) 1992-10-29

Family

ID=24741366

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1992/000723 Ceased WO1992018531A1 (fr) 1991-04-09 1992-04-01 Analogues de somatocrinine

Country Status (10)

Country Link
US (1) US5846936A (fr)
EP (2) EP0542937A1 (fr)
JP (1) JPH05507939A (fr)
AU (1) AU662731B2 (fr)
CA (1) CA2084061A1 (fr)
IE (1) IE921121A1 (fr)
IL (1) IL101452A (fr)
NZ (1) NZ242209A (fr)
WO (1) WO1992018531A1 (fr)
ZA (1) ZA922420B (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0708179A3 (fr) * 1994-10-18 1996-08-28 Lilly Co Eli Analogues de peptides insulinotropes de type glucagon, ocompositions et méthode d'utilisation
WO1997040071A1 (fr) * 1996-04-19 1997-10-30 Novo Nordisk A/S Composes capables de liberer une hormone de croissance
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5981488A (en) * 1997-03-31 1999-11-09 Eli Lillly And Company Glucagon-like peptide-1 analogs
WO2002062844A3 (fr) * 2001-02-02 2003-08-21 Conjuchem Inc Derives du facteur de liberation de l'hormone de croissance de longue duree
DE10111022B4 (de) 2000-03-08 2005-08-25 Volkmar Heuser Hochwärmedämmendes Fenster oder Tür
US7199217B2 (en) 2000-12-13 2007-04-03 Eli Lilly And Company Amidated glucagon-like peptide-1

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0922446A1 (fr) * 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Préparation des conjugués du GRF-PEG par un méthode en solution spécifique à un site
US6696063B1 (en) 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
US20040192593A1 (en) * 1999-07-26 2004-09-30 Baylor College Of Medicine Protease resistant ti-growth hormone releasing hormone
WO2001006988A2 (fr) 1999-07-26 2001-02-01 Baylor College Of Medicine Analogue superactif de la somatostatine porcine
US6486134B2 (en) * 1999-09-17 2002-11-26 Leadergene Limited Gene treatment to enhance feed efficiency and growth rate of livestock
CA2380423A1 (fr) * 2000-05-17 2001-11-22 Bionebraska, Inc. Preparations pharmaceutiques peptidiques
WO2003038112A2 (fr) 2001-10-26 2003-05-08 Baylor College Of Medicine Composition et methode permettant de modifier la masse maigre et les proprietes osseuses d'un sujet
MY142457A (en) * 2001-12-11 2010-11-30 Advisys Inc Plasmid mediated supplementation for treating chronically ill subjects
WO2003066825A2 (fr) * 2002-02-07 2003-08-14 Baylor College Of Medicine Developpement modifie de l'hypophyse chez la progeniture de femelles animales portantes traitees par la therapie hormonale de liberation de l'hormone de croissance
WO2004027064A2 (fr) * 2002-09-18 2004-04-01 Centre Hospitalier De L'universite De Montreal (Chum) Analogues de ghrh
CA2513743C (fr) * 2003-01-28 2013-06-25 Advisys, Inc. Reduction de reforme dans l'hormone de croissance (ghrh) d'animaux de troupeau
TW200424214A (en) * 2003-04-21 2004-11-16 Advisys Inc Plasmid mediated GHRH supplementation for renal failures
EP1660530A2 (fr) * 2003-08-04 2006-05-31 Advisys, Inc. Hormone liberant une hormone de croissance specifique du chien
US8188056B2 (en) * 2003-12-31 2012-05-29 Vgx Pharmaceuticals, Inc. Reducing arthritis and lameness in subjects by growth hormone releasing hormone (GHRH) supplementation
EP1713828B1 (fr) * 2004-01-20 2011-04-27 VGX Pharmaceuticals, LLC Secretion/retention ameliorees de somatostatine par des cellules musculaires au moyen de peptides signal specifiques de l'espece
JP2008507537A (ja) * 2004-07-23 2008-03-13 アドバイシーズ，インコーポレイテッド 予防接種レスポンスを増強する成長ホルモン放出ホルモン
US8058253B2 (en) * 2006-07-06 2011-11-15 Vgx Pharmaceuticals, Inc. Growth hormone releasing hormone treatment to decrease cholesterol levels
BRPI0720306A2 (pt) 2006-12-14 2014-02-04 Aileron Therapeutics Inc Sistemas de macrociclização da bis-sufidrila
DK2118123T3 (en) 2007-01-31 2016-01-25 Dana Farber Cancer Inst Inc Stabilized p53 peptides and uses thereof
CN101730708B (zh) 2007-03-28 2013-09-18 哈佛大学校长及研究员协会 缝合多肽
WO2009009727A2 (fr) * 2007-07-12 2009-01-15 Akela Pharma Srl Analogues de la ghrh et leurs utilisations thérapeutiques
EP3473643A1 (fr) 2008-06-12 2019-04-24 Ipsen Bioinnovation Limited Protéines de fusion pour leur utilisation dans le traitement du cancer
EP2421547A1 (fr) * 2009-04-20 2012-02-29 Theratechnologies Inc. Utilisation de (hexénoyl trans-3)hgrf(1-44)nh2 et de ritonavir dans une polythérapie
WO2010121352A1 (fr) * 2009-04-20 2010-10-28 Theratechnologies Inc. Utilisation de (hexénoyl trans-3)hgrf(1-44)nh2 et de simvastatine dans un traitement combiné
WO2011153491A2 (fr) 2010-06-03 2011-12-08 University Of Miami Agonistes de l'hormone de libération de l'hormone de croissance en tant qu'effecteurs de la survie et de la prolifération d'îlots pancréatiques
WO2012021875A1 (fr) 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques à coupleurs triazole
US8361964B2 (en) 2011-04-21 2013-01-29 Theratechnologies Inc. Growth hormone releasing factor (GRF) analogs and uses thereof
US9096684B2 (en) 2011-10-18 2015-08-04 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US9079974B2 (en) * 2011-12-21 2015-07-14 The University Of Miami GH-RH analogs with potent agonistic effects
JP6450192B2 (ja) 2012-02-15 2019-01-09 エイルロン セラピューティクス，インコーポレイテッド トリアゾール架橋した、およびチオエーテル架橋したペプチドミメティック大環状化合物
AR089993A1 (es) 2012-02-15 2014-10-01 Aileron Therapeutics Inc Macrociclos peptidomimeticos
WO2013190520A2 (fr) 2012-06-22 2013-12-27 The General Hospital Corporation Agents de libération de gh dans le traitement d'une sténose vasculaire et d'états associés
JP6526563B2 (ja) 2012-11-01 2019-06-05 エイルロン セラピューティクス，インコーポレイテッド 二置換アミノ酸ならびにその調製および使用の方法
EP2935317B1 (fr) 2012-12-21 2019-03-27 University of Miami Agonistes de ghrh pour la greffe et fonction de cellules d'îlot et le traitement du diabète
US9855312B2 (en) 2012-12-21 2018-01-02 University Of Miami GHRH agonists for the treatment of ischemic disorders
SG10201902594QA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
US10563174B2 (en) * 2014-09-24 2020-02-18 University Of Oregon Proteins increasing pancreatic beta cell number and methods of use
CA2979847A1 (fr) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Macrocycles peptidomimetiques et leurs utilisations
WO2017004548A1 (fr) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques
WO2017181277A1 (fr) 2016-04-19 2017-10-26 Griffon Pharmaceuticals Inc. Peptides pégylés bioactifs et utilisations correspondantes

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0326418A1 (fr) * 1988-01-29 1989-08-02 The Upjohn Company Analogues GRF
EP0365779A2 (fr) * 1988-09-06 1990-05-02 F. Hoffmann-La Roche Ag Analogues cycliques de GRF II
WO1990008776A1 (fr) * 1989-01-27 1990-08-09 The Upjohn Company Analogues de grf puissants et stabilises
WO1990015821A1 (fr) * 1989-06-16 1990-12-27 The Upjohn Company Analogues stabilises de grf a action puissante

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4618598A (en) * 1982-04-12 1986-10-21 Duke University Method of regulating hormone function or release
US4517181A (en) * 1982-09-15 1985-05-14 The Salk Institute For Biological Studies Mammalian PGRF
US4529595A (en) * 1983-01-13 1985-07-16 The Salk Institute For Biological Studies GRF Analogs
US4728726A (en) * 1982-10-04 1988-03-01 The Salk Institute For Biological Studies GRF analogs IIIb
US4703035A (en) * 1982-10-04 1987-10-27 The Salk Institute For Biological Studies Human pancreatic GRF amidated fragments
US4595676A (en) * 1983-04-26 1986-06-17 The Salk Institute For Biological Studies Rat hypothalamic GRF
US4563352A (en) * 1982-10-04 1986-01-07 The Salk Institute For Biological Studies Human pancreatic GRF
US4518586A (en) * 1983-01-13 1985-05-21 The Salk Institute For Biological Studies GRF Analogs III
IL70530A (en) * 1983-01-13 1986-09-30 Salk Inst For Biological Studi Synthetic peptides having growth hormone releasing factor activity and compositions containing them
DE3482387D1 (en) * 1983-03-07 1990-07-05 Hoffmann La Roche Polypeptide.
US4732972A (en) * 1983-03-07 1988-03-22 Hoffmann-La Roche Inc. Polypeptides having growth hormone releasing activity
US4628043A (en) * 1983-04-26 1986-12-09 The Salk Institute For Biological Studies Hypothalamic GRF agonists
US4605643A (en) * 1984-03-02 1986-08-12 The Salk Institute For Biological Studies Ovine GRF
US4585756A (en) * 1983-10-12 1986-04-29 The Salk Institute For Biological Studies Bovine GRF
US4610976A (en) * 1983-08-29 1986-09-09 The Salk Institute For Biological Studies Porcine GRF
US4626523A (en) * 1983-09-13 1986-12-02 The Salk Institute For Biological Studies GRF analogs II
US4617149A (en) * 1983-09-21 1986-10-14 Eli Lilly And Company Growth hormone release factor analogs
US4528190A (en) * 1983-10-25 1985-07-09 The Salk Institute For Biological Studies GRF Analogs IV
US4562175A (en) * 1984-02-03 1985-12-31 Ding Chang Synthetic peptides
US4649039A (en) * 1984-07-03 1987-03-10 E. I. Du Pont De Nemours And Company Radiolabeling of methionine-containing proteins and peptides
US4649131A (en) * 1984-09-24 1987-03-10 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US4622312A (en) * 1984-09-24 1986-11-11 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US4734399A (en) * 1985-08-06 1988-03-29 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US4689318A (en) * 1985-08-29 1987-08-25 The Salk Institute For Biological Studies GRF analogs
US4783524A (en) * 1985-09-17 1988-11-08 Monsanto Company Growth factors
US4784987A (en) * 1987-01-13 1988-11-15 The Salk Institute For Biological Studies GRF analogs VI
US4914189A (en) * 1987-02-05 1990-04-03 The Adminstrators Of The Tulane Educational Fund Synthetic GHRH analogs
US5002931A (en) * 1987-05-22 1991-03-26 The Salk Institute For Biological Studies GRF analogs VII
US5043322A (en) * 1988-07-22 1991-08-27 The Salk Institute For Biological Studies Cyclic GRF analogs

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0326418A1 (fr) * 1988-01-29 1989-08-02 The Upjohn Company Analogues GRF
EP0365779A2 (fr) * 1988-09-06 1990-05-02 F. Hoffmann-La Roche Ag Analogues cycliques de GRF II
WO1990008776A1 (fr) * 1989-01-27 1990-08-09 The Upjohn Company Analogues de grf puissants et stabilises
WO1990015821A1 (fr) * 1989-06-16 1990-12-27 The Upjohn Company Analogues stabilises de grf a action puissante

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
International Journal of Peptide & Protein Research, vol. 36, no. 6, December 1990, (Copenhagen, DK), M. ZARANDI et al.: "Synthesis and in vitro and in vivo activity of analogs of growth hormone-releasing hormone (GH-RH) with C-terminal agmatine", pages 499-505, see the whole article *
J. MARTINEZ: "Peptide Hormones as Prohormones: Processing, Biological activity, Pharmacology", pages 230-231, Ellis Horwood Ltd, Chichester, GB, see pages 230-231 *
Peptides 1988 Proceedings of the 20th European Peptide Symposium, Tübingen, 4-9 September 1988, (editors G. JUNG et al.), Walter de Gruyter, (Berlin, DE), A.M. FELIX et al.: "Design, synthesis and biological activity of highly potent growth hormone releasing factor analogs", pages 601-603, see the whole article *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6388053B1 (en) 1993-12-09 2002-05-14 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US6410513B1 (en) 1993-12-09 2002-06-25 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5977071A (en) * 1993-12-09 1999-11-02 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US7232879B2 (en) 1993-12-09 2007-06-19 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US6133235A (en) * 1993-12-09 2000-10-17 Eli Lilly And Company Glucagon-like insulinotropic peptides compositions and methods
US6703365B2 (en) 1993-12-09 2004-03-09 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
EP0708179A3 (fr) * 1994-10-18 1996-08-28 Lilly Co Eli Analogues de peptides insulinotropes de type glucagon, ocompositions et méthode d'utilisation
EP1227151A1 (fr) * 1994-10-18 2002-07-31 Eli Lilly And Company Analogues de peptides insulinotropes de type glucagon, compositions et méthode d'utilisation
WO1997040071A1 (fr) * 1996-04-19 1997-10-30 Novo Nordisk A/S Composes capables de liberer une hormone de croissance
US5981488A (en) * 1997-03-31 1999-11-09 Eli Lillly And Company Glucagon-like peptide-1 analogs
DE10111022B4 (de) 2000-03-08 2005-08-25 Volkmar Heuser Hochwärmedämmendes Fenster oder Tür
US7199217B2 (en) 2000-12-13 2007-04-03 Eli Lilly And Company Amidated glucagon-like peptide-1
WO2002062844A3 (fr) * 2001-02-02 2003-08-21 Conjuchem Inc Derives du facteur de liberation de l'hormone de croissance de longue duree
US7268113B2 (en) 2001-02-02 2007-09-11 Conjuchem Biotechnologies Inc. Long lasting growth hormone releasing factor derivatives

Also Published As

Publication number Publication date
EP0525838A3 (fr) 1993-02-10
AU1448592A (en) 1992-11-17
IL101452A (en) 1996-11-14
IL101452A0 (en) 1992-12-30
ZA922420B (en) 1992-12-30
NZ242209A (en) 1994-04-27
IE921121A1 (en) 1992-10-21
EP0525838A2 (fr) 1993-02-03
JPH05507939A (ja) 1993-11-11
CA2084061A1 (fr) 1992-10-10
US5846936A (en) 1998-12-08
AU662731B2 (en) 1995-09-14
EP0542937A1 (fr) 1993-05-26

Similar Documents

Publication Publication Date Title
US5846936A (en) Growth hormone releasing factor analogs
EP0177819B1 (fr) Analogues du facteur libérant l'hormone de croissance et leur procédé
US5696089A (en) Histidine substituted growth hormone releasing factor analogs
US4622312A (en) Growth hormone releasing factor analogs
FI88402C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara grf-analoger
US5084442A (en) Cyclic growth hormone releasing factor analogs and method for the manufacture thereof
US6057422A (en) Antagonistic analogs of GH-RH inhibiting IGF-I and -II
US4734399A (en) Growth hormone releasing factor analogs
US20150274798A1 (en) Novel gh-rh analogs with potent agonistic effects
CA1254000A (fr) Analogues du facteur de liberation de l'hormone de croissance
JP2715472B2 (ja) 環式ペプチド
US4732972A (en) Polypeptides having growth hormone releasing activity
US4959352A (en) Cyclic growth hormone releasing factor analogs and method for the manufacture thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

WWE Wipo information: entry into national phase

Ref document number: 2084061

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1992907635

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1992907635

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1992907635

Country of ref document: EP